nf-кb

AP-1/NF-κB activation inhibitor 1 is a potent inhibitor of AP-1 and NF-κB mediated transcriptional activation ( IC 50 =1 μM), does not blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells [1].

The NF-κB Activation Inhibitor III, controls the biological activity of NF-κB. It is primarily used for Inflammation/Immunology applications.

NF-κB-IN-2 inhibits canonical NF-κB signaling induced by TNF-α in PC-3 cells.

NF-κB/PON1-IN-1 (Compound 16) is an NF-κB/PON1 pathway inhibitor with antioxidant activity (IC50: 45.76 μM) and hepatoprotective activity.

Akt/NF-κB/MAPK-IN-1 (compound 2m) serves as a potent, orally active inhibitor targeting NO with an IC50 of 7.70 μM and demonstrates low toxicity. This compound exerts anti-inflammatory effects by impeding the Akt/NF-κB and MAPK signaling pathways [1].

NF-κB inhibitor is a synthetic peptide corresponding to the nuclear localization sequence (NLS) of NF-κB p105 subunit (also known as p50) appended to a hydrophobic sequence to facilitate import into living cells. It blocks the nuclear import of p105 in cells treated with activators of NF-κB signaling, including LPS and TNF-α. NF-κB control is a peptide that is identical in sequence to NF-κB inhibitor, except two essential, basic residues of the p105 NLS are substituted with non-basic amino acids. It is ineffective at blocking the activation of NF-κB signaling and is used as a negative control peptide.

NF-κB-IN-13 (compound 12) markedly suppresses LPS-induced NF-κB activation and NO synthesis in RAW264.7 macrophages, exhibiting anti-inflammatory properties [1].

BOT-64 is an IKK-2 inhibitor which targets the Ser177 and/or Ser181 residues in the kinase's activation loop domain.BOT-64 is a cell-permeable benzoxathiole compound

NF-κB-IN-9, a nuclear factor kappa B (NF-κB) targeting sonosensitizer with excitation and emission wavelengths (λex/λem) of 489/628 nm, features dual resveratrol units that strongly inhibit NF-κB signaling. This compound demonstrates notable anti-tumor properties and pronounced sonocytotoxicity against cancer cells, maintaining biosafety in xenograft mouse models.

NF-κB-IN-5 (compound 4d) is an orally active NF-κB inhibitor. NF-κB-IN-5 interacts directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines, with IC 50 values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM for HCT116, U87-MG, HepG2, BGC823, PC9, respectively.

NF-κB/MAPK-IN-1 is a potent dual inhibitor of the NF-κB and MAPK pathways with potential anti-inflammatory activity, inhibition of NO production, and inhibition of LPS-induced activation of iNOS, COX-2, ERΚ and P38. NF-κB/MAPK-IN-1 is used for the prevention and treatment of rheumatoid arthritis (RA).

NF-κB-IN-10 (compound E1) is an inhibitor of NF-κB that mitigates heart failure symptoms through the modulation of the Nrf2/NF-κB signaling pathway, alleviating oxidative stress and inflammation. It suppresses LPS-induced NO production and downregulates iNOS and COX-2 expression in RAW264.7 cells, showing potential for research in cardiovascular diseases [1].

NF-κB-IN-8 is a competitive antagonist of LPS for MD-2 binding, and it impedes the expression of inflammatory factors by engaging MD-2. Additionally, it inhibits ALP activity and is usable in inflammation research, including acute lung injury (ALI) [1].

NF-κB-IN-4 (compound 17) is a potent inhibitor of NF-κB pathway which can cross blood brain barrier (BBB). NF-κB-IN-4 shows potential anti-neuroinflammatory activity with low toxicity which can be used for the research of neuroinflammation related diseases. NF-κB-IN-4 can block the IκBα activation and phosphorylation, reduce NLRP3 expression, therefore inhibiting NF-κB activation [1].

TLR4/NF-κB/MAPK-IN-1 is a novel antineuroinflammatory agent that functions by inhibiting the TLR4/NF-κB/MAPK pathways.

NF-κB-IN-12 (compound 3h) serves as a potent inhibitor of NF-κB, exhibiting an IC50 value of 1.02 μM. It is applicable for research in acute lung injury [1].

NF-κB-IN-11 (Compound 3i) is an inhibitor of NF-κB, effectively blocking TNF-α-induced NF-κB pathway activation and the nuclear translocation of NF-κB. It also reduces the expression levels of phospho-IKK, IκBα, and NF-κB p65. Demonstrating anti-inflammatory properties, NF-κB-IN-11 mitigates dextran sulfate sodium-induced colitis in mice and exhibits a maximum tolerated dose (MTD) exceeding 1852 mg/kg in acute toxicity assays when administered orally (p.o.) [1].

NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent that works by reducing the protein expression of iNOS and COX-2 by suppressing the NF-κB signaling pathway. NF-κB-IN-6 inhibits the production of NO in LPS-induced RAW264.7 cells with an IC50 of 23.1 μM[1].

NF-κB-IN-3 (Compound 2) is an NF-κB inhibitor (IC50: 0.70 μM) and can be used as an anti-tumour agent.

Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signalling pathways.Akt/NF-κB/JNK-IN-1 exhibits an inhibitory effect on nitric oxide production (IC50: 3.15 μM) and shows anti-inflammatory effects.

NF-κB-IN-1 (1,6-Heptadiene-3,5-dione, 1,7-bis(3,4-dimethoxyphenyl)-4-[(4-hydroxy-3-methoxyphenyl)methylene]-, (1E,6E)-) is a potent NF-κB signaling pathway inhibitor. It is a 4-arylidene crucumin analogue. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells.

RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.

Cloxacillin sodium monohydrate (Cloxacillin Sodium) is the sodium salt of cloxaclliin, a semisynthetic beta-lactamase resistant penicillin antibiotic with antibacterial activity.

Cloxacillin, an orally active antibacterial agent and β-lactamase inhibitor, exhibits an IC50 of 0.04 µM. It effectively suppresses S. aureus-induced inflammatory responses by inhibiting the activation of MAPKs, NF-кB, and NLRP3-related proteins.